Novartis Quarterly Profit Misses Estimates Amid Alcon Woes

  • Drugmaker appoints new CEO for Alcon unit as its sales drop
  • Novartis forecasts 2016 sales, profit to be unchanged

Novartis CEO on Alcon Growth Plan, Patents, Pricing

Novartis AG, Europe’s second-largest drugmaker, posted fourth-quarter earnings that missed analysts’ estimates as revenue at its Alcon eye-care unit continued to plummet and the strength of the U.S. dollar eroded the value of global sales.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.